The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis
Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various maligna...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2020-12, Vol.99 (51), p.e23837-e23837 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e23837 |
|---|---|
| container_issue | 51 |
| container_start_page | e23837 |
| container_title | Medicine (Baltimore) |
| container_volume | 99 |
| creator | Koh, Hyun Min Hyun, Chang Lim Jang, Bo Gun Lee, Hyun Ju |
| description | Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC).
Eligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC.
The pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P |
| doi_str_mv | 10.1097/MD.0000000000023837 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_1097_MD_0000000000023837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473740690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3552-1e7ca9017132b38945b3d34c1b23dc3b1f14f53e072e9b6633991709e03f378a3</originalsourceid><addsrcrecordid>eNpdkc1u1TAQhSMEopfCEyAhL9mk2B4njlkgVS1_Uis2ZW05zuQmkNgX27nRfQWeGre3lJ9ZeKTxme_YOkXxktEzRpV8c315Rv8Uhwbko2LDKqjLStXicbHJ06qUSoqT4lmM3yhlILl4WpwAgGSsFpvi582AJOBk0uhdHMYdaTGtiI4MuDPJz6bsMIx77Mg2-DUNpDc2-UCM68gu-K3zcYxkdMR5V8bZTBOxmI9pcVtijbMY3pJzEg8x4ZxdbHbbj7jeAWZMpjTOTIcMeV486c0U8cV9Py2-fnh_c_GpvPry8fPF-VVpoap4yVBaoyiTDHgLjRJVCx0Iy1oOnYWW9Uz0FSCVHFVb1wBKMUkVUuhBNgZOi3dH7m5pZ-wsuhTMpHdhnE04aG9G_e-NGwe99XstpWiAqgx4fQ8I_seCMel5jLefNg79EjUXEqSgtaJZCkepDT7GgP2DDaP6NkV9fan_TzFvvfr7hQ87v2PLAnEUrH5KGOL3aVkx6AHNlIY7XiUVLznllHHW0DJHzzj8Ar4lqf0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473740690</pqid></control><display><type>article</type><title>The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis</title><source>IngentaConnect</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Wolters Kluwer Open Access</source><creator>Koh, Hyun Min ; Hyun, Chang Lim ; Jang, Bo Gun ; Lee, Hyun Ju</creator><creatorcontrib>Koh, Hyun Min ; Hyun, Chang Lim ; Jang, Bo Gun ; Lee, Hyun Ju</creatorcontrib><description>Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC).
Eligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC.
The pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P < .001) and 2.77 (95% CI 1.79-4.29, P < .001) for overall survival and disease-free survival, respectively. High HDGF expression was significantly correlated with a larger tumor size (OR 1.59, 95% CI 1.02-2.46, P = .040).
HDGF expression is related to clinical outcome and may be a prognostic marker in patients with NSCLC.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000023837</identifier><identifier>PMID: 33371164</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Biomarkers, Tumor - analysis ; Biomarkers, Tumor - blood ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - mortality ; Disease-Free Survival ; Humans ; Intercellular Signaling Peptides and Proteins - analysis ; Intercellular Signaling Peptides and Proteins - blood ; Prognosis ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2020-12, Vol.99 (51), p.e23837-e23837</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3552-1e7ca9017132b38945b3d34c1b23dc3b1f14f53e072e9b6633991709e03f378a3</cites><orcidid>0000-0002-0335-5996</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748309/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748309/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33371164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koh, Hyun Min</creatorcontrib><creatorcontrib>Hyun, Chang Lim</creatorcontrib><creatorcontrib>Jang, Bo Gun</creatorcontrib><creatorcontrib>Lee, Hyun Ju</creatorcontrib><title>The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC).
Eligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC.
The pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P < .001) and 2.77 (95% CI 1.79-4.29, P < .001) for overall survival and disease-free survival, respectively. High HDGF expression was significantly correlated with a larger tumor size (OR 1.59, 95% CI 1.02-2.46, P = .040).
HDGF expression is related to clinical outcome and may be a prognostic marker in patients with NSCLC.</description><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Intercellular Signaling Peptides and Proteins - analysis</subject><subject>Intercellular Signaling Peptides and Proteins - blood</subject><subject>Prognosis</subject><subject>Systematic Review and Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1u1TAQhSMEopfCEyAhL9mk2B4njlkgVS1_Uis2ZW05zuQmkNgX27nRfQWeGre3lJ9ZeKTxme_YOkXxktEzRpV8c315Rv8Uhwbko2LDKqjLStXicbHJ06qUSoqT4lmM3yhlILl4WpwAgGSsFpvi582AJOBk0uhdHMYdaTGtiI4MuDPJz6bsMIx77Mg2-DUNpDc2-UCM68gu-K3zcYxkdMR5V8bZTBOxmI9pcVtijbMY3pJzEg8x4ZxdbHbbj7jeAWZMpjTOTIcMeV486c0U8cV9Py2-fnh_c_GpvPry8fPF-VVpoap4yVBaoyiTDHgLjRJVCx0Iy1oOnYWW9Uz0FSCVHFVb1wBKMUkVUuhBNgZOi3dH7m5pZ-wsuhTMpHdhnE04aG9G_e-NGwe99XstpWiAqgx4fQ8I_seCMel5jLefNg79EjUXEqSgtaJZCkepDT7GgP2DDaP6NkV9fan_TzFvvfr7hQ87v2PLAnEUrH5KGOL3aVkx6AHNlIY7XiUVLznllHHW0DJHzzj8Ar4lqf0</recordid><startdate>20201218</startdate><enddate>20201218</enddate><creator>Koh, Hyun Min</creator><creator>Hyun, Chang Lim</creator><creator>Jang, Bo Gun</creator><creator>Lee, Hyun Ju</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0335-5996</orcidid></search><sort><creationdate>20201218</creationdate><title>The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis</title><author>Koh, Hyun Min ; Hyun, Chang Lim ; Jang, Bo Gun ; Lee, Hyun Ju</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3552-1e7ca9017132b38945b3d34c1b23dc3b1f14f53e072e9b6633991709e03f378a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Intercellular Signaling Peptides and Proteins - analysis</topic><topic>Intercellular Signaling Peptides and Proteins - blood</topic><topic>Prognosis</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koh, Hyun Min</creatorcontrib><creatorcontrib>Hyun, Chang Lim</creatorcontrib><creatorcontrib>Jang, Bo Gun</creatorcontrib><creatorcontrib>Lee, Hyun Ju</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koh, Hyun Min</au><au>Hyun, Chang Lim</au><au>Jang, Bo Gun</au><au>Lee, Hyun Ju</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-12-18</date><risdate>2020</risdate><volume>99</volume><issue>51</issue><spage>e23837</spage><epage>e23837</epage><pages>e23837-e23837</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Hepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC).
Eligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC.
The pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P < .001) and 2.77 (95% CI 1.79-4.29, P < .001) for overall survival and disease-free survival, respectively. High HDGF expression was significantly correlated with a larger tumor size (OR 1.59, 95% CI 1.02-2.46, P = .040).
HDGF expression is related to clinical outcome and may be a prognostic marker in patients with NSCLC.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>33371164</pmid><doi>10.1097/MD.0000000000023837</doi><orcidid>https://orcid.org/0000-0002-0335-5996</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2020-12, Vol.99 (51), p.e23837-e23837 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_MD_0000000000023837 |
| source | IngentaConnect; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library; Wolters Kluwer Open Access |
| subjects | Biomarkers, Tumor - analysis Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - mortality Disease-Free Survival Humans Intercellular Signaling Peptides and Proteins - analysis Intercellular Signaling Peptides and Proteins - blood Prognosis Systematic Review and Meta-Analysis |
| title | The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A11%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relationship%20between%20hepatoma-derived%20growth%20factor%20and%20prognosis%20in%20non-small%20cell%20lung%20cancer:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Koh,%20Hyun%20Min&rft.date=2020-12-18&rft.volume=99&rft.issue=51&rft.spage=e23837&rft.epage=e23837&rft.pages=e23837-e23837&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000023837&rft_dat=%3Cproquest_pubme%3E2473740690%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473740690&rft_id=info:pmid/33371164&rfr_iscdi=true |